Renal function in African women receiving tenofovir disoproxil fumarate as pre‐exposure prophylaxis for HIV during pregnancy and postpartum: A postpartum safety analysis in the CAP016 randomized control trial

Documenti analoghi

• Metabolic effects of switching to Biktarvy (B/F/TAF) in patients with HIV‐1 treated with antiretroviral regimens that do not include tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF): The Metabic study
  di: C. Busca‐Arenzana, et al.
  Pubblicazione: (2024)
• Intracellular tenofovir‐diphosphate concentrations in HIV pre‐exposure prophylaxis users who underwent bariatric surgery
  di: Matthew W. McGarrity, et al.
  Pubblicazione: (2025)
• Hepatitis B reactivation in people living with HIV and isolated anti‐ HBc receiving tenofovir‐sparing dual antiretroviral therapy
  di: M. D. M. Arcos‐Rueda, et al.
  Pubblicazione: (2026)
• Pre-exposure prophylaxis (PrEP) against HIV: efficacy, safety and uncertainties
  di: Matilde Sánchez-Conde
  Pubblicazione: (2017)
• TelePrEP in Italy: A remote service to expand equitable access to HIV pre‐exposure prophylaxis
  di: Maria Luisa Cosmaro, et al.
  Pubblicazione: (2025)